Literature DB >> 9496189

The use of cyclosporin in corticosteroid dependent asthma.

M E Coren1, M Rosenthal, A Bush.   

Abstract

Five children with severe asthma requiring at least 10 mg of prednisolone daily were treated with cyclosporin. Three were weaned from prednisolone, but one quickly relapsed. One girl had her steroid dose lowered but suffered unacceptable hirsutism and one child failed to respond. Cyclosporin may be useful in refractory childhood asthma. A prospective study is required to confirm this.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9496189      PMCID: PMC1717405          DOI: 10.1136/adc.77.6.522

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  6 in total

1.  Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma.

Authors:  M Azzawi; B Bradley; P K Jeffery; A J Frew; A J Wardlaw; G Knowles; B Assoufi; J V Collins; S Durham; A B Kay
Journal:  Am Rev Respir Dis       Date:  1990-12

Review 2.  Alternative pharmacotherapies for steroid-dependent asthma.

Authors:  R B Moss
Journal:  Chest       Date:  1995-03       Impact factor: 9.410

3.  Alternative treatments for asthma: assessing the need.

Authors:  S J Szefler; A K Kamada; D Hughes; A M Brenner; E W Gelfand
Journal:  J Asthma       Date:  1992       Impact factor: 2.515

4.  Glucocorticoid resistance in chronic asthma. Peripheral blood T lymphocyte activation and comparison of the T lymphocyte inhibitory effects of glucocorticoids and cyclosporin A.

Authors:  C J Corrigan; P H Brown; N C Barnes; J J Tsai; A J Frew; A B Kay
Journal:  Am Rev Respir Dis       Date:  1991-11

5.  Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma.

Authors:  S H Lock; A B Kay; N C Barnes
Journal:  Am J Respir Crit Care Med       Date:  1996-02       Impact factor: 21.405

6.  CD4 T-lymphocyte activation in acute severe asthma. Relationship to disease severity and atopic status.

Authors:  C J Corrigan; A B Kay
Journal:  Am Rev Respir Dis       Date:  1990-04
  6 in total
  12 in total

Review 1.  Difficult asthma: beyond the guidelines.

Authors:  I Balfour-Lynn
Journal:  Arch Dis Child       Date:  1999-02       Impact factor: 3.791

Review 2.  Asthma--the changing face of drug therapy.

Authors:  J Legg; J Warner
Journal:  Indian J Pediatr       Date:  2000-02       Impact factor: 1.967

Review 3.  Difficult asthma in children.

Authors:  S A McKenzie; A Bush
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

Review 4.  Management of severe asthma in children.

Authors:  Andrew Bush; Sejal Saglani
Journal:  Lancet       Date:  2010-09-04       Impact factor: 79.321

Review 5.  Treatment of severe small airways disease in children with cystic fibrosis: alternatives to corticosteroids.

Authors:  Adam Jaffe; Ian M Balfour-Lynn
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

6.  Safety and ethics of bronchoscopy and endobronchial biopsy in difficult asthma.

Authors:  D Payne; S A McKenzie; S Stacey; D Misra; E Haxby; A Bush
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

Review 7.  Management of unresponsive asthma.

Authors:  S K Kabra; R Lodha
Journal:  Indian J Pediatr       Date:  2004-08       Impact factor: 1.967

Review 8.  Severe asthma in children.

Authors:  Theresa W Guilbert; Leonard B Bacharier; Anne M Fitzpatrick
Journal:  J Allergy Clin Immunol Pract       Date:  2014 Sep-Oct

9.  Assessment of the effectiveness of cyclosporine nasal spray in an animal model of allergic rhinitis.

Authors:  Erol Senturk; Yavuz Selim Yildirim; Remzi Dogan; Orhan Ozturan; Eray Metin Guler; Mehmet Serif Aydin; Abdurrahim Kocyigit; Mukaddes Esrefoglu; Ilker Kocak
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-10-25       Impact factor: 2.503

10.  Therapeutic options for severe asthma.

Authors:  Jilcy Mathew; Wilbert S Aronow; Dipak Chandy
Journal:  Arch Med Sci       Date:  2012-09-08       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.